Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator
Authors:
- G-One AhnGAG-One Ahn
- K. Jane BottingKBK. Jane Botting
- Adam V. PattersonAPAdam V. Patterson
- David C. WareDWDavid C. Ware
- Moana TercelMTMoana Tercel
- William R. WilsonWWWilliam R. Wilson
- 1 June 2006
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 71 (12) , 1683-1694
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Tumor microenvironmental physiology and its implications for radiation oncologySeminars in Radiation Oncology, 2004
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004
- The hypoxic tumour microenvironment and metastatic progressionClinical & Experimental Metastasis, 2003
- Hypoxia as a target for combined modality treatmentsEuropean Journal of Cancer, 2002
- Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcomeRadiotherapy and Oncology, 1999
- Oxygenation predicts radiation response and survival in patients with cervix cancerRadiotherapy and Oncology, 1998
- Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neckRadiotherapy and Oncology, 1996
- Cellular pharmacology of quinone bioreductive alkylating agentsCancer and Metastasis Reviews, 1993
- The experimental development of bioreductive drugs and their role in cancer therapyCancer and Metastasis Reviews, 1993
- The hypoxic tumor cell: A target for selective cancer chemotherapyBiochemical Pharmacology, 1980